Autologous transplantation for multiple myeloma
نویسندگان
چکیده
منابع مشابه
Autologous transplantation for multiple myeloma.
Until now high-dose therapy (HDT) supported by autologous stem cell transplantation (ASCT) has been considered the standard of care for frontline therapy of multiple myeloma (MM) in younger patients with normal renal function, and MM is currently the first indication of ASCT. However, the introduction of the novel agents thalidomide, bortezomib and lenalidomide is changing the scenario in two w...
متن کاملSingle versus double autologous stem-cell transplantation for multiple myeloma.
BACKGROUND We conducted a randomized trial of the treatment of multiple myeloma with high-dose chemotherapy followed by either one or two successive autologous stem-cell transplantations. METHODS At the time of diagnosis, 399 previously untreated patients under the age of 60 years were randomly assigned to receive a single or double transplant. RESULTS A complete or a very good partial resp...
متن کاملAutologous stem cell transplantation for multiple myeloma: history and future
Over the last decade, high-dose therapy supported by autologous stem cell transplantation (ASCT) has been the standard frontline therapy for younger patients with multiple myeloma (MM). But recently, the treatment strategy has been dramatically changed after the introduction of novel agents such as thalidomide, bortezomib and lenalidomide. These agents have been incorporated into induction ther...
متن کاملAutologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma without Cryopreservation
High-dose chemotherapy followed by autologous hematopoietic stem cell transplantation is considered the standard of care for multiple myeloma patients who are eligible for transplantation. The process of autografting comprises the following steps: control of the primary disease by using a certain induction therapeutic protocol, mobilization of stem cells, collection of mobilized stem cells by a...
متن کاملAutologous transplantation and maintenance therapy in multiple myeloma.
BACKGROUND This open-label, randomized, phase 3 study compared melphalan at a dose of 200 mg per square meter of body-surface area plus autologous stem-cell transplantation with melphalan-prednisone-lenalidomide (MPR) and compared lenalidomide maintenance therapy with no maintenance therapy in patients with newly diagnosed multiple myeloma. METHODS We randomly assigned 273 patients 65 years o...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Annals of Oncology
سال: 2008
ISSN: 0923-7534
DOI: 10.1093/annonc/mdn449